Ex Vivo High-Throughput Assay for Vaginal Community Post-menopausal Women (FLORA)

February 22, 2016 updated by: Kimberly-Clark Corporation

Development of an Ex-vivo High-throughput Screening Assay for the Vaginal Microbiota of Post-menopausal Women

This purpose of this study is to collect vaginal microbial samples of postmenopausal women to assess the optimal conditions for cultivation and storage of the vaginal microbiota. These samples will subsequently be used to develop a high-throughput assay that mimicks the vaginal microbial community of postmenopausal women. This assay will be used to select and screen compounds that can affect the vaginal microbiota and subsequently affect related symptoms such as vaginal dryness.

Study Overview

Status

Completed

Detailed Description

Vaginal swabs will be collected from post-menopausal women (5 women vaginal pH ≤4.5 and 5 women with vaginal pH≥5.5), aged 45 - 75, with at least 12 months of amenorrhea. Enough women will be screened to ensure five women for each pH range.

Using a speculum, the mid lateral vaginal wall is made visible, samples will be collected by the physician or nurse using a flocked swab. After collection, vaginal swabs will be stored immediately in adequate liquid medium at 4ºC and will be transported to the lab within 7 hours after sampling for further storage and culture of the material.

The vaginal microbiota of post-menopausal women with a vaginal pH of ≤ 4.5 and ≥ 5.5 will be characterized and compared using 16S ribosomal ribonucleic acid (rRNA) sequencing. In additional, optimal conditions for cultivation and storage of the vaginal microbiota will be examined for use in assays mimicking the vaginal microbial community of postmenopausal women.

Study Type

Observational

Enrollment (Actual)

10

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Groningen, Netherlands, 9700
        • University Medical Center Groningen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Post-menopausal women

Description

Inclusion Criteria:

  1. Agree to study design (signed informed consent)
  2. Post-menopausal women
  3. Vaginal pH ≤4.5 or pH ≥5.5
  4. At least 12 months of amenorrhea
  5. Age ≥45 and ≤75
  6. Currently in a mutually monogamous sexual relationship or not sexually active;
  7. Sexually abstinent 48 hours prior to visit.
  8. Willing and capable of following all study instructions; and
  9. Good general health.

Exclusion Criteria:

  1. Vaginal pH between >4.5 and <5.5
  2. Use of topical estrogen containing product 1 week prior to enrollment
  3. Use of vaginal lubricants, douches, or any products applied vaginally during the week prior to the first visit
  4. Use of systemic estrogen therapy or products 6 months prior to inclusion
  5. Use of a vaginal pessary during the week prior to the visit
  6. Excessive alcohol usage (>4 consumptions/day or >20 consumptions/week)
  7. Drug usage within past 2 years
  8. A history or currently undergoing immunosuppressive drug therapy, chemotherapy, or radiation therapy
  9. A medical condition which might compromise immune system functions (such as cancer, leucopenia, HIV-positive, or organ transplant)
  10. Antibiotics and/or anti-fungal medication use within the last four (4) weeks
  11. Induced menopause due to surgical or medical interventions, such as bilateral oophorectomy, hysterectomy, chemotherapy or radiation treatment
  12. Currently diagnosed with or being treated for a genital infection or urinary tract infection, subjects who had any vaginal infection one month prior to the screening will be excluded
  13. Individuals with a sexually transmitted disease (self-reported or detected by the Principal Investigator)
  14. At enrollment, have any social or medical condition, or psychiatric illness that, in the opinion of the Investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
  15. Participation in a clinical trial involving an investigational product/device within the past three months; subjects who are scheduled to participate in another clinical study concurrently.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Low pH
Post Menopausal women with vaginal pH of 4.5 or below
High pH
Post Menopausal women with vaginal pH of 5.5 or above

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Characterization of the microbiota
Time Frame: 0 hours
By 16s rRNA sequencing
0 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ellen Klinkert, MD, Department of Gynaecology, University Medical Center Groningen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2015

Primary Completion (Actual)

February 1, 2016

Study Completion (Actual)

February 1, 2016

Study Registration Dates

First Submitted

April 9, 2015

First Submitted That Met QC Criteria

April 13, 2015

First Posted (Estimate)

April 14, 2015

Study Record Updates

Last Update Posted (Estimate)

February 23, 2016

Last Update Submitted That Met QC Criteria

February 22, 2016

Last Verified

February 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • 500-14-0004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postmenopausal Syndrome

3
Subscribe